Intercostal catheter for analgesia post minimally invasive mitral valve surgery: A randomised, double blind study.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00015650

Enrollment

Registered

2018-10-04

Start date

2013-10-08

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia post minimally invasive mitral valve surgery I34.0

Interventions

Group 1: Intraoperatively placement of an intercostal catheter at the site of thoracotomy

via this catheter bolus at the end of operation: 0,25 ml/kg bodyweight ropivacain 0,75%

continuously during 48 hours ropivacain 0,2% @ 0,1 ml/kg bodyweight/h (ie 0,1 ml/kg bodyweight/hour) Group 2: Intraoperatively Placement of an intercostal caheter at the site of thoracotomy

via this catheter bolus at the end of operation NaCl 0,9% 0,25 ml/kg bodyweight

continously during 48 hours NaCl 0,9% @ 0,1, ml/kg/h

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Minimally invasive mitral valve surgery.

Exclusion criteria

Exclusion criteria: Allergy against the medication put to use; ongoing use of antidepressants, antipsychotics, and analgetics; unability to use the VAS score.

Design outcomes

Primary

Measure	Time frame
Piritramid consumption during 8 hours postoperatively. The aim ist a score of 3 or below on the VAS; responsible for interviewing the Patient are the nursing staff.	—

Secondary

Measure	Time frame
Ventilator time, Hospital time, Maximum VAS scores.	—

Countries

Germany

Contacts

Public ContactMechthild Ziegler

Universitätsklinikum Ul,. Sektion Kardioanästhesiologie

mechthild.ziegler@uniklinik-ulm.de0731 - 500 - 55422

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026